Related Experiment Video
Updated: May 6, 2026
11:07
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
Published on: April 14, 2022
2.1K
Update on juvenile myasthenia gravis
1Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, USA.
Current Opinion in Pediatrics
|October 22, 2013
Summary
Juvenile myasthenia gravis shares similarities with adult forms but has unique aspects. Thymectomy shows promise for selected pediatric cases, though more research is needed.
Area of Science:
- Neurology
- Autoimmune Disorders
- Pediatrics
Background:
- Juvenile myasthenia gravis (JMG) is a rare autoimmune neuromuscular disease.
- Its pathophysiology mirrors adult myasthenia gravis (MG) but presents distinct clinical features and treatment considerations.
- Limited research exists specifically for JMG due to its rarity.
Purpose of the Study:
- To review the pathophysiology, clinical presentation, and treatment options for JMG.
- To highlight the differences and similarities between JMG and adult MG.
- To assess current therapeutic strategies for JMG.
Main Methods:
- Review of existing literature on juvenile myasthenia gravis.
- Analysis of clinical experience from a referral center.
- Evaluation of retrospective series and adult MG studies.
Main Results:
- Randomized clinical trials for MG are predominantly in adult populations.
- Thymectomy is a potential therapeutic option for selected generalized JMG cases, supported by retrospective data and clinical experience.
- Efficacy and treatment outcomes in JMG are challenging to evaluate due to limited prospective data.
Conclusions:
- Adult MG research offers insights but is not a complete substitute for pediatric-specific studies.
- Dedicated research in pediatric populations is crucial for advancing JMG understanding and treatment.
- While some adult findings are applicable, distinct research is necessary for juvenile myasthenia gravis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:15Myasthenia Gravis: Diagnostic Tests
3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
01:22Myasthenia Gravis ll: Pathophysiology
75
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
75
01:28Disorders of the Skeletal Muscle
2.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.3K
01:26Chemical Synapses
9.5K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.5K
01:26Chemical Synapses
10.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.9K